The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
0606007 Informal Interpretation
Business Opportunity Rule - 16 CFR Part 437 (Extending Comment Period on Proposed Rule)
20061064: Merck & Co., Inc.; GlycoFi, Inc.
20060573: GATX Corporation; Oglebay Norton Company
0605031 Informal Interpretation
Johnson & Johnson, In the Matter of
The consent order protects competition in three medical device product markets affected by Johnson & Johnson’s proposed $25.4 billion acquisition of Guidant Corporation. Under the terms of the order, J&J is required to 1) grant to a third party a 6 fully paid-up, non-exclusive, irrevocable license, enabling that third party to make and sell drug eluting stents with the Rapid Exchange delivery system, 2) divest to a third party J&J’s endoscopic vessel harvesting product line, and 3) end its agreement to distribute Novare Surgical System, Inc.’s proximal anastomotic assist device. On May 31st, 2006 the Commission granted a petition filed by Johnson and Johnson Corporation, requesting that the FTC reopen and set aside the entire decision and order concerning the proposed acquisition of Guidant Corporation.